Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (7): 689-692.doi: 10.35541/cjd.20201086
• Reviews • Previous Articles Next Articles
Jiang Xiaoyan1, Gao Min2, Zhang Xiaoyan3, Liu Ningyuan1
Received:2020-11-12
Revised:2022-03-07
Online:2023-07-15
Published:2023-07-04
Contact:
Zhang Xiaoyan
E-mail:superfawn@aliyun.com
Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.doi:10.35541/cjd.20201086
| ［1］ | Setta⁃Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis⁃associated pustular phenotypes［J］. J Invest Dermatol, 2013,133（5）:1366⁃1369. doi: 10.1038/jid.2012.490 |
| ［2］ | Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies［J］. Clin Rev Allergy Immunol, 2018,54（1）:102⁃113. doi: 10.1007/s12016⁃018⁃8668⁃1. |
| ［3］ | Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study （UNCOVER⁃J）［J］. J Dermatol, 2017,44（4）:355⁃362. doi: 10.1111/1346⁃8138.13622. |
| ［4］ | Okubo Y, Mabuchi T, Iwatsuki K, et al. Long⁃term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open⁃label, phase 3 study （UNCOVER⁃J）［J］. J Eur Acad Dermatol Venereol, 2019,33（2）:325⁃332. doi: 10.1111/jdv.15287. |
| ［5］ | Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab［J］. J Dermatolog Treat, 2021,32（1）:117⁃119. doi: 10.1080/09546634.2019.1628170. |
| ［6］ | Pilz AC, Roenneberg S, Biedermann T, et al. Ixekizumab for acrodermatitis continua［J］. J Dtsch Dermatol Ges, 2018,16（7）:907⁃910. doi: 10.1111/ddg.13568. |
| ［7］ | Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phase III open⁃label multicenter Japanese study［J］. J Dermatol, 2016,43（9）:1011⁃1017. doi: 10.1111/1346⁃8138.13306. |
| ［8］ | Wilsmann⁃Theis D, Schnell LM, Ralser⁃Isselstein V, et al. Successful treatment with interleukin⁃17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations［J］. J Dermatol, 2018,45（7）:850⁃854. doi: 10.1111/1346⁃8138.14318. |
| ［9］ | Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis［J］. J Dermatol, 2020,47（3）:e77⁃77e78. doi: 10.1111/1346⁃8138.15228. |
| ［10］ | Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work［J］. J Dermatol, 2018,45（11）:1353⁃1356. doi: 10.1111/1346⁃8138.14636. |
| ［11］ | Molho⁃Pessach V, Alyan R, Gordon D, et al. Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent［J］. JAMA Dermatol, 2017,153（5）:473⁃475. doi: 10.1001/jamadermatol.2016.5705. |
| ［12］ | Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report［J］. Acta Derm Venereol, 2020,100（15）:adv00251. doi: 10.2340/ 00015555⁃3611. |
| ［13］ | Balestri R, Rech G, Tasin L, et al. Acrodermatitis continua of Hallopeau successfully treated with secukinumab［J］. J Dermatolog Treat, 2018,29（sup1）:3⁃5. doi: 10.1080/09546634. 2018.1527993. |
| ［14］ | Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab［J］. JAAD Case Rep, 2017,3（3）:215⁃218. doi: 10.1016/j.jdcr.2017.02.016. |
| ［15］ | Smirnova LM, Vertieva EY, Olisova OY, et al. Outcomes of various types of therapy in patients with treatment⁃resistant acrodermatitis continua of Hallopeau［J］. Biologics, 2019,13:83⁃87. doi: 10.2147/BTT.S199100. |
| ［16］ | Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial［J］. J Am Acad Dermatol, 2017,76（1）:70⁃80. doi: 10.1016/j.jaad.2016.07.058. |
| ［17］ | Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52⁃week, open⁃label study［J］. Br J Dermatol, 2017,176（3）:741⁃751. doi: 10.1111/bjd. 14702. |
| ［18］ | Passante M, Dastoli S, Nisticò SP, et al. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: a case report［J］. Dermatol Ther, 2020,33（1）:e13170. doi: 10.1111/dth. 13170. |
| ［19］ | Nakao M, Asano Y, Kamata M, et al. Successful treatment of palmoplantar pustular psoriasis with brodalumab［J］. Eur J Dermatol, 2018,28（4）:538⁃539. doi: 10.1684/ejd.2018.3325. |
| ［20］ | Pinter A, Wilsmann⁃Theis D, Peitsch WK, et al. Interleukin⁃17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases［J］. J Dermatol, 2019,46（5）:426⁃430. doi: 10.1111/1346⁃8138.14815. |
| ［21］ | Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study［J］. J Dermatol, 2018,45（5）:529⁃539. doi: 10.1111/1346⁃8138.14294. |
| ［22］ | Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2019,155（10）:1153⁃1161. doi: 10.1001/jamadermatol.2019.1394. |
| ［23］ | Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（3）:309⁃316. doi: 10.1001/jamadermatol. 2017.5937. |
| ［24］ | Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status［J］. JAMA Dermatol, 2016,152（7）:825⁃828. doi: 10.1001/jamadermatol. 2016.0751. |
| ［25］ | Storan ER, O', Gorman SM, et al. Generalized pustular psoriasis treated with ustekinumab［J］. Clin Exp Dermatol, 2016,41（6）:689⁃690. doi: 10.1111/ced.12868. |
| ［26］ | Daudén E, Santiago⁃et⁃Sánchez⁃Mateos D, Sotomayor⁃López E, et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis［J］. Br J Dermatol, 2010,163（6）:1346⁃1347. doi: 10.1111/j.1365⁃2133.2010.09995.x. |
| ［27］ | Palacios⁃Álvarez I, Simal⁃Gómez G, Mas⁃Vidal A, et al. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti⁃TNF agents［J］. J Dtsch Dermatol Ges, 2018,16（5）:611⁃613. doi: 10.1111/ddg.13506. |
| ［28］ | Adışen E, Özer İ, Temel B, et al. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti⁃TNF agents［J］. Dermatol Ther, 2017,30（2）doi: 10.1111/dth.12460. |
| ［29］ | Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra［J］. Dermatology, 2015,230（2）:97⁃100. doi: 10.1159/000367690. |
| ［30］ | Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau［J］. J Eur Acad Dermatol Venereol, 2020,34（10）:2330⁃2338. doi: 10.1111/jdv.16265. |
| ［31］ | Bertelsen T, Kragballe K, Johansen C, et al. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis［J］. Int J Dermatol, 2014,53（10）:e464⁃e466. doi: 10.1111/ijd.12511. |
| ［32］ | Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis［J］. Br J Dermatol, 2010,163（5）:1116⁃1118. doi: 10.1111/j.1365⁃2133.2010.09897.x. |
| ［33］ | Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ustekinumab in palmoplantar pustulosis［J］. J Eur Acad Dermatol Venereol, 2018,32（5）:e204⁃204e206. doi: 10.1111/jdv.14718. |
| ［34］ | Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis［J］. Expert Opin Drug Saf, 2020,19（8）:969⁃980. doi: 10.1080/14740338.2020.1785427. |
| [1] | Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705. |
| [2] | Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650. |
| [3] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
| [4] | China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401. |
| [5] | Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360. |
| [6] | Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368. |
| [7] | He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278. |
| [8] | Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322. |
| [9] | Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203. |
| [10] | Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251. |
| [11] | Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215. |
| [12] | Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210794-e20210794. |
| [13] | Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220869-e20220869. |
| [14] | Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220271-e20220271. |
| [15] | Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875. |
|
